A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive
Status:
Withdrawn
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the effect of oral contraceptive (birth control pill) on the blood
level of lanabecestat when both are given together. Side effects will be monitored and
documented. This study will last up to 27 days for each participant, not including screening.
Screening is required within 42 days prior to first dose.